Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

121.86 +3.08 (+2.59%)
Streaming Delayed Price Updated: 3:35 PM EST, Dec 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
68 69 Next >
News headline image
Positive News is Driving This Cancer Drug Maker’s Stock Higher
IDEAYA Biosciences stock is up more than 16% on positive treatment data in a Phase 2 clinical trial, but after a 76% run-up, IDYA stock may need a breather 
Via MarketBeat
News headline image
3 Dividend Growth Stocks to Buy and Hold ↗
What's better than a dividend? A dividend that's growing. 
Via The Motley Fool
News headline image
Is Iovance Biotherapeutics a Millionaire Maker? ↗
This biotech's future is bright, but how good could it get for investors? 
Via The Motley Fool
News headline image
The 7 Most Undervalued Healthcare Stocks to Buy in July 2024 ↗
Explore undervalued healthcare stocks offering growth potential and stability in contrast to overvalued tech sector. 
Via InvestorPlace
News headline image
Gilead Sciences's Options Frenzy: What You Need to Know ↗
 
Via Benzinga
News headline image
Looking Into Gilead Sciences's Recent Short Interest ↗
 
Via Benzinga
News headline image
If You Invested $1000 In This Stock 20 Years Ago, You Would Have $8,400 Today ↗
 
Via Benzinga
News headline image
Key Takeaways From Gilead Sciences Analyst Ratings ↗
 
Via Benzinga
News headline image
3 Underappreciated Stocks About to Break Their Chains ↗
Explore these underappreciated stocks ready for growth and get an in-depth analysis, forecasts, and news on these potential breakout stocks. 
Via InvestorPlace
News headline image
Oil Declines Amid Prospects Of An Agreement Between Israel And Hamas. Powell Will Address The Us Congress Today ↗
On Monday, the Dow Jones (US30) decreased by 0.08%, while the S&P 500 (US500) added 0.10%. The NASDAQ Technology Index (US100) closed positive 0.28%. 
Via Talk Markets
Topics Stocks
News headline image
7 Cheap Biotech Stocks With Major Upside Potential ↗
While the broader healthcare sector enjoys permanent relevance, you can potentially maximize your upside with cheap biotech stocks. 
Via InvestorPlace
News headline image
Healthcare Stocks Continue To Lag The Market-Can Anything Help ? ↗
Healthcare stocks continue to lag the market up about 6% YTD, helped by Large Cap Biopharma but hurt by United Health. 
Via Talk Markets
News headline image
This Domino's Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday ↗
 
Via Benzinga
News headline image
Gilead Sciences's Options Frenzy: What You Need to Know ↗
 
Via Benzinga
News headline image
Amgen, Inc. Dividend Stock Analysis ↗
Amgen Inc. is one of the world's leading biotech companies with major treatments for anemia, neutropenia, rheumatoid and psoriatic arthritis, psoriasis, cancer and osteoporosis. 
Via Talk Markets
News headline image
FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals ↗
Biotech stocks are on the verge of a comeback after a period of underperformance amid a wave of FDA approvals. 
Via InvestorPlace
News headline image
3 Undervalued Biotech Gems With 200%+ Analyst Price Targets ↗
These three undervalued biotech stocks have begun garnering investor attention as their treatments show promise. 
Via InvestorPlace
News headline image
3 Magnificent Stocks Retirees Can Buy and Hold Forever ↗
These stocks could be ideal for investors in their golden years. 
Via The Motley Fool
News headline image
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields ↗
 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
7 Dividend Stocks to Buy Now: June 2024 ↗
These dividend stocks to buy now will reward investors with income now and growth as the market breadth expands. 
Via InvestorPlace
News headline image
DraftKings And Dell Were Among The 10 Biggest Large Cap Stock Gainers Last Week (June 16-June 22): Are These In Your Portfolio? ↗
Top performers last week were SRPT (+29.50%), SIRI (+16.73%), TOST (+15.57%), GILD (+12.62%), CHWY (+10.59%), ACN (+9.80%), DKNG (+9.69%), DELL (+8.19%), ADSK (+7.99%), and GFI (+7.15%). 
Via Benzinga
News headline image
MarketBeat Week in Review – 6/17 - 6/21
Markets were calmer this week, with the Dow index posting the biggest gains, but it's too early to tell if this is the start of a broader market rally 
Via MarketBeat
Topics Economy Stocks
News headline image
Top Analyst Reports For Abbott, BP & Gilead ↗
Today's Research Daily features new research reports on 16 major stocks, including Abbott Laboratories, BP p.l.c.and Gilead Sciences, Inc., as well as two micro-cap stocks Smith-Midland Corp. and... 
Via Talk Markets
News headline image
Nvidia Snaps 8-Week Winning Run, S&P 500 Marks Longest Streak Without A 2% Drop Since Great Recession, Oil Prices Stage Comeback: This Week In The Market ↗
Stock market rally continues with new highs in S&P 500 and Nasdaq 100, driven by tech and semiconductor sectors, but concerns arise over lack of broad participation and high concentration in mega-cap... 
Via Benzinga
Topics Economy Stocks
News headline image
Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments ↗
Gilead Sciences faces Wall Street speculation about its potential in the obesity drug market despite its focus on liver treatments. 
Via Benzinga
News headline image
Why Gilead Sciences Stock Is Trading Higher Friday ↗
On Thursday before the market opened, Gilead announced efficacy data for its possible HIV prevention drug, Lenacapavir. 
Via Benzinga
News headline image
Pre-Market Movers - June 21, 2024 ↗
Sarepta jumps after announcing expanded approval of DMD drug and more news on today's top movers. 
Via Talk Markets
News headline image
Gilead Sciences Stock Surges on HIV Treatment Trial Success
Gilead Sciences (NASDAQ: GILD) saw its stock jump nearly 10% yesterday after announcing groundbreaking results from its HIV treatment trial. 
Via MarketBeat
News headline image
Defying the Norms: 3 High P/E Stocks With Room to Run ↗
Gilead Sciences, Crowdstrike and DataDog might be the best high P/E stocks to buy, offering substantial growth despite elevated valuations. 
Via InvestorPlace
< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
68 69 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.